anlotinib + durvalumab + tislelizumab

This combination therapy regimen is being investigated for the treatment of extensive-stage small cell lung cancer (ES-SCLC). The regimen consists of **anlotinib**, a multi-targeted tyrosine kinase inhibitor (TKI), administered in combination with a PD-1/L1 checkpoint inhibitor, specifically either **durvalumab** (a PD-L1 inhibitor) or **tislelizumab** (a PD-1 inhibitor). This treatment is evaluated as a sequential therapy following induction chemotherapy and thoracic radiotherapy. Anlotinib works by inhibiting multiple receptor tyrosine kinases involved in angiogenesis and tumor growth, including VEGFR, FGFR, PDGFR, and c-Kit. The PD-1/L1 inhibitors function by blocking the interaction between programmed cell death protein 1 and its ligands, thereby enhancing the anti-tumor immune response. This specific combination is the focus of the Phase 2 **AVATAR** clinical trial led by investigator Xiaorong Dong.

Brand names

ImfinziTevimbra

Other names

anlotinib + PD-1/L1 inhibitoranlotinib + durvalumabanlotinib + tislelizumab